Pharmacopoeial medicines and carton markings: dosage-range compliance and manufacturer identification did not create Tariff Item 14E liability.

Analgin tablets covered by the Indian Pharmacopoeia and the National Formulary of India were treated as pharmacopoeial preparations because the notified editions of those publications applied and the tablets fell within the prescribed dosage range. The mere presence of the manufacturer's name, symbol or monogram on the carton did not, by itself, make the product a patent or proprietary medicine; proprietary character required a trade connection shown by the marking. The rule-compliance objection also failed because the recognised pharmacopoeial abbreviation appeared on the carton. On that basis, classification under Tariff Item 14E was not justified.

---

---

Issues: (i) Whether the analgin tablets were pharmacopoeial preparations excluded from Tariff Item 14E, having regard to the notified editions of the National Formulary of India and the Government clarification on dosage range and usual strength; (ii) whether the presence of the manufacturer's name, symbol or monogram on the carton made the product a patent or proprietary medicine within Tariff Item 14E; and (iii) whether the alleged non-compliance with Rule 96 ZN(2) of the Central Excise Rules, 1944 was established.

Issue (i): Whether the analgin tablets were pharmacopoeial preparations excluded from Tariff Item 14E, having regard to the notified editions of the National Formulary of India and the Government clarification on dosage range and usual strength.

Analysis: Tariff Item 14E applied only where the drug was not specified in a monograph in a notified pharmacopoeia, formulary or publication. The product was admittedly covered by the Indian Pharmacopoeia and the National Formulary of India. The notification under the Explanation to Item 14E expressly notified all editions of the specified pharmacopoeias and formularies, so the 1966 and 1979 editions could not be rejected as inapplicable merely because they were later or earlier editions. The Government clarification further provided that where a pharmacopoeia prescribes a usual strength and also a dosage range, preparations marketed within that dosage range are to be treated as pharmacopoeial. The tablets fell within the relevant dosage range.

Conclusion: The tablets were pharmacopoeial preparations and were not classifiable under Tariff Item 14E on this ground.

Issue (ii): Whether the presence of the manufacturer's name, symbol or monogram on the carton made the product a patent or proprietary medicine within Tariff Item 14E.

Analysis: A proprietary character arose only if the medicine bore a name, brand or mark indicating a trade connection with a person having the right to use it as proprietor or otherwise. The mere statutory appearance of the manufacturer's name on the carton did not, by itself, establish such proprietary connection. No material showed that the carton presentation converted the product into a brand-name medicine.

Conclusion: The carton markings did not bring the product within the proprietary-medicine limb of Tariff Item 14E.

Issue (iii): Whether the alleged non-compliance with Rule 96 ZN(2) of the Central Excise Rules, 1944 was established.

Analysis: The record showed that the recognised abbreviation of the relevant pharmacopoeia appeared below the drug name on the carton, which satisfied the rule's requirement.

Conclusion: No violation of Rule 96 ZN(2) was made out.

Final Conclusion: The demand could not be sustained because the product was a notified pharmacopoeial preparation falling within the prescribed dosage range, and neither the carton markings nor the rule-compliance objection justified classification under Tariff Item 14E.

Ratio Decidendi: Where a drug is specified in a notified pharmacopoeia or formulary and is marketed within the prescribed dosage range, it remains pharmacopoeial for tariff purposes, and statutory manufacturer identification on the carton does not by itself make it a patent or proprietary medicine.

---